# Matinas BioPharma Holdings, Inc. (MTNB)

> Matinas BioPharma Holdings, Inc. (MTNB) trades at $1.19 (+2.59%) as of 8:00:00 PM EST on Nov 6, 2026, -57.95% over the past month. Market cap is $1.17M, with 1.0 days to cover in short interest.

Canonical: https://massive.com/quote/mtnb
Data as of: 2026-11-07T01:00:00.017Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.19** +0.03 (+2.59%)
At close · 15-minute delayed
NYSE American · usd

After hours: **$1.19** +0.06 (+5.04%)
As of 8:00:00 PM EST on Nov 6, 2026 · After hours

## Stock performance

How Matinas BioPharma Holdings, Inc. (MTNB) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.59% |
| 1W | -21.19% |
| 1M | -57.95% |
| YTD | -86.46% |
| 1Y | -93.22% |
| 52-wk range | $0.97 – $19.95 |

From daily closes through Nov 6, 2026.

## Key statistics

Today's trading snapshot for MTNB: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.12 – $1.25 |
| Open | $1.22 |
| Prev close | $1.16 |
| Volume | 35.66K |
| Market cap | $1.17M |
| Shares out | 979.52K |

## Valuation and profitability ratios

Valuation and profitability ratios for Matinas BioPharma Holdings, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.65 |
| P/FCF | — |
| ROE | -406.1% |
| ROA | -214.2% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 6, 2026

## Insider trading

[Matinas BioPharma Holdings, Inc. (MTNB) insider trading](https://massive.com/quote/mtnb/insider-trading.md): open-market Form 4 buys and sells by Matinas BioPharma Holdings, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Matinas BioPharma Holdings, Inc. has disclosed to the SEC on Form 8-K.

- Nov 3, 2026 · Deal termination
  “On November 3, 2026, Matinas BioPharma Holdings, Inc. (the "Company") and a former financial advisor to the Company (the "Advisor") terminated the agreement between the Company and the Advisor.”
- Sep 28, 2026 · Charter amendment
  “On September 25, 2026, Matinas BioPharma Holdings, Inc. ... filed a Certificate of Amendment to the Company's Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware.”
- Sep 16, 2026 · [Stock split](https://massive.com/quote/sec-filings/8-k/stock-splits.md)
  “On September 16, 2026, the Company announced that the Board has approved a reverse stock split of the Common Stock at a ratio of one-for-fifteen (1:15) (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on September 28, 2026.”
- Sep 4, 2026 · [Listing deficiency notice](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “As previously disclosed, the Company also received written notices from the NYSE American indicating that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide.”
- Jul 24, 2026 · Deal termination
  “On July 23, 2026, pursuant to and in accordance with Section 12(a) of the Sales Agreement, BTIG notified the Company that BTIG is terminating the Sales Agreement, effective immediately. The Company is not subject to any termination penalties or other expenses related to the termination of the Sales Agreement.”

## Dividend history and stock splits

Matinas BioPharma Holdings, Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-15 · Sep 28, 2026
- 1-for-50 · Sep 3, 2024

## MTNB short interest

How heavily MTNB is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.0 |
| Short interest | 49.43K |
| Avg volume | 129.62K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## MTNB news

The latest news and headlines about Matinas BioPharma Holdings, Inc. (MTNB).

- [Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards](https://www.globenewswire.com/news-release/2026/09/04/3356817/32419/en/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards.html) · GlobeNewswire Inc. · Sep 4, 2026 · negative sentiment
- [Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance](https://www.globenewswire.com/news-release/2026/06/26/3318484/32419/en/Matinas-BioPharma-Receives-Notice-of-Non-Compliance-with-NYSE-American-Continued-Listing-Standards-and-Acceptance-of-Plan-to-Regain-Compliance.html) · GlobeNewswire Inc. · Jun 26, 2026 · negative sentiment
- [Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program](https://www.globenewswire.com/news-release/2024/06/24/2902970/32419/en/Matinas-BioPharma-Reports-Successful-Treatment-of-Patient-with-Limb-Threatening-Mucor-Infection-in-its-Oral-MAT2203-Compassionate-Expanded-Use-Access-Program.html) · GlobeNewswire Inc. · Jun 24, 2024
- [Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin](https://www.globenewswire.com/news-release/2024/06/13/2898142/32419/en/Matinas-BioPharma-s-Oral-MAT2203-to-Be-Featured-in-Fireside-Chat-Hosted-by-A-G-P-with-Antifungal-Expert-Dr-David-S-Perlin.html) · GlobeNewswire Inc. · Jun 13, 2024
- [New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024](https://www.globenewswire.com/news-release/2024/05/16/2883246/32419/en/New-In-Vitro-Data-Showing-Matinas-BioPharma-s-LNC-Platform-Delivering-Small-Oligonucleotides-Presented-at-TIDES-USA-2024.html) · GlobeNewswire Inc. · May 16, 2024

## About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

| Measure | Value |
| --- | --- |
| Exchange | NYSE American |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Listed | Jul 21, 2014 |

[Company website](https://www.matinasbiopharma.com)

## FAQ

### What is the Matinas BioPharma Holdings, Inc. (MTNB) stock price today?

Matinas BioPharma Holdings, Inc. (MTNB) is trading at $1.19 (+2.59% on the day) as of 8:00:00 PM EST on Nov 6, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Matinas BioPharma Holdings, Inc.?

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

### What is the short interest in MTNB?

As of Oct 15, 2026, MTNB has 49.43K shares short and 1.0 days to cover.

### What exchange is MTNB listed on?

Matinas BioPharma Holdings, Inc. (MTNB) trades on NYSE American in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time MTNB quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=MTNB`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Matinas BioPharma Holdings, Inc. (MTNB) insider trading](https://massive.com/quote/mtnb/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms